Table 3.
Association between baseline disease characteristicsa and symptom duration at first PRh assessment
| Total cohort (n = 507) | |||||||
|---|---|---|---|---|---|---|---|
| Symptoms ≤4 months 228 | Symptoms >4 months 279 | P-value | Symptoms >6 months 215 | P-value (compared with ≤4 months) | Symptoms >12 months 108 | P-value compared with ≤4 months | |
| Age, (yrs) | 6.5 (2.9, 10.8) | 7.3 (3.2, 10.9) | NS | 7.4 (3.1, 11.2) | NS | 6.6 (2.9, 10.3) | NS |
| Female, n (%) | 141 (62) | 186 (66) | NS | 140 (65) | NS | 68 (63) | NS |
| Active joint count | 1 (1, 3) | 2 (1, 6) | 0.005 | 2 (1, 6) | 0.006 | 2 (1, 8) | 0.001 |
| Limited joint count | 1 (0, 2) | 1 (0, 4) | 0.007 | 1 (1, 4) | 0.005 | 2 (1, 4) | 0.009 |
| CHAQ (0–3) | 0.75 (0.13, 1.38) | 0.63 (0.13, 1.5) | NS | 0.63 (0.13, 1.50) | NS | 0.56 (0, 1.50) | NS |
| Physician global assessment (0–100) | 37 (20, 64) | 33 (20, 56) | NS | 34 (20, 58) | NS | 35 (26, 57) | NS |
| Parent global assessment (0–100) | 18 (4, 47) | 20 (5, 46) | NS | 20 (5, 45) | NS | 21 (5, 48) | NS |
| Pain (0–100) | 34 (6, 61) | 34 (10, 60) | NS | 33 (10, 57) | NS | 33 (10, 60) | NS |
| ESR (mm/h)b | 32 (12, 57) | 14 (5, 32) | <0.001 | 11 (5, 30) | <0.001 | 8 (4, 22) | <0.001 |
| ESR ≤10 mm/h, n (%) | 39 (23) | 98 (46) | <0.001 | 79 (48) | <0.001 | 45 (56) | <0.001 |
| CRP (mg/l) | 12 (4,48) | 7 (3, 20) | 0.002 | 7 (0, 19) | 0.0002 | 5 (0, 14) | <0.001 |
| Acute uveitis, n (%) | 4 (1.8) | 3 (1.3) | NS | 3 (1.4) | NS | 2 (1.9) | NS |
| Chronic uveitis, n (%) | 3 (1.4) | 7 (2.6) | NS | 5 (2.4) | NS | 3 (2.9) | NS |
aResults are presented as median (Interquartile range) unless stated otherwise. bESR available in 389 children only (174 with oligoarthritis).